Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells $153,185.76 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert Goeltz II sold 6,552 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $23.38, for a total value of $153,185.76. Following the completion of the sale, the chief financial officer owned 67,924 shares of the company’s stock, valued at $1,588,063.12. This represents a 8.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $23.22 on Monday. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The stock’s fifty day moving average price is $22.39 and its 200-day moving average price is $15.17. The firm has a market cap of $2.51 billion, a P/E ratio of -6.75 and a beta of 0.77. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $26.40.

Arcus Biosciences (NYSE:RCUS) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The firm’s quarterly revenue was down 45.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.00) EPS. On average, equities research analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Wells Fargo & Company lifted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 20th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research note on Monday, December 15th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 14th. Finally, HC Wainwright lifted their target price on Arcus Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $28.89.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its position in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after buying an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. boosted its holdings in Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of Arcus Biosciences during the third quarter worth about $69,000. CWM LLC increased its holdings in shares of Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in shares of Arcus Biosciences by 34.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after purchasing an additional 1,796 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.